Molecular Formula | C19H21ClN2O3S |
Molar Mass | 392.9 |
Density | 1.329g/cm3 |
Melting Point | 193-194°C |
Boling Point | 666.324°C at 760 mmHg |
Flash Point | 356.78°C |
Water Solubility | Soluble in water (<1 mg/ml at 25°C), DMF, methanol, ethanol (4 mg/ml at 25°C), and DMSO (79 mg/ml at 25°C). |
Solubility | DMSO : 100 mg/mL (254.52 mM; Need ultrasonic) |
Vapor Presure | 0mmHg at 25°C |
Appearance | White to off-white (Solid) |
Color | white to off-white |
Merck | 14,7452 |
Storage Condition | 2-8°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
Refractive Index | 1.64 |
MDL | MFCD04975446 |
Physical and Chemical Properties | The appearance is white crystal powder, and the melting range is 193-194 ℃. |
Use | A new generation of drugs for the treatment of type 2 diabetes |
Hazard Symbols | Xi - Irritant |
Risk Codes | R36/38 - Irritating to eyes and skin. R36 - Irritating to the eyes |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
WGK Germany | 3 |
RTECS | XJ5813440 |
HS Code | 29341000 |
Hazard Class | IRRITANT |
Reference Show more | 1. [IF=5.81] Yin Jing et al."Danggui-Shaoyao-San Improves Gut Microbia Dysbiosis and Hepatic Lipid Homeostasis in Fructose-Fed Rats."Front Pharmacol. 2021 Jul;0:1752 |
colorless prismatic crystals were obtained from ethanol with a melting point of 193-194 °c.
- (5-ethyl-2-pyridyl) ethanol is condensed with p-fluoronitrobenzene, and the resulting compound is then reduced to an amine and then diazotized in acetone-methanol containing hydrobromic acid, methyl acrylate was further added for coupling, followed by condensation and cyclization with thiourea, and then hydrolysis to give pioglitazone.
research and development of the pharmaceutical industry in Koita, Japan. Approved by the U. S. Food and Drug Administration in 1999. Insulin sensitizer, for a new generation of Type II diabetes treatment drugs, side effects. It reduces insulin resistance in peripheral tissues and liver, increases insulin-dependent glucose processing, and reduces hepatic glucose output. Pioglitazone improves insulin sensitivity in patients with insulin resistance, increases insulin responsiveness to cells, and improves glucose homeostasis disorders. For the treatment of diabetes.